INVECTA: Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications

INVECTA：针对治疗应用的新型腺病毒载体的综合表征

• 批准号: EP/Y036883/1
• 负责人: Alan Parker
• 金额: $ 2.98万
• 依托单位: CARDIFF UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FY036883%2F1
• 关键词: INVECTA; Integrative; characterisation; Novel; adenovirus

Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting their thorough investigation. Therefore, the main objective of INVECTA is to establish a collaborative effort for the study of scientific problems related to development of novel low seroprevalence adenovirus based vectors aimed at their therapeutic usage, with an emphasis on training both experienced and early stage researchers in adenovirus research, as well as establishing foundation for long term collaboration. As the use of adenoviral based platforms becomes widespread there is a pressing need to develop protocols and methodologies to define the full complement of adenovirus-host interactions, the "adenoviral interactome", that may limit efficacy and compromise safety. Within INVECTA we aim to increase our understanding of novel low seroprevalence adenovirus vectors with respect to infectivity, structure, stability, receptor usage, tropism, and the interaction with the blood and immune system. This knowledge willallow us to evaluate novel low seroprevalence vectors at the pre-clinical level in areas of unmet clinical need, namely cancer gene therapy and vaccination. INVECTA presents an interdisciplinary and intersectoral network in basic and translational adenovirus research which will foster transfer of knowledge, skills and technology, as well as enable training in the field of basic and applicative adenovirus biology. To maximize knowledge sharing, INVECTA will second researchers within consortium, organize internal workshops and training sessions, and strongly encourage participation in specialized workshops, schools and conferences according to the open science model.

基于腺病毒的载体具有潜在的转化和商业价值，并作为基因转移和疫苗接种的载体进行研究。低血清流行率腺病毒是载体设计的有效平台，值得对其进行彻底研究。因此，INVECTA 的主要目标是建立合作伙伴关系，研究与开发新型低血清阳性率腺病毒载体相关的科学问题，旨在其治疗用途，重点是培训腺病毒研究方面经验丰富的和早期的研究人员，并为长期合作奠定基础。随着基于腺病毒的平台的使用变得广泛，迫切需要开发方案和方法来定义腺病毒-宿主相互作用的完整补充，即“腺病毒相互作用组”，这可能会限制功效并损害安全性。在 INVECTA 中，我们的目标是加深对新型低血清阳性率腺病毒载体在感染性、结构、稳定性、受体使用、向性以及与血液和免疫系统的相互作用方面的了解。这些知识将使我们能够在未满足临床需求的领域（即癌症基因治疗和疫苗接种）的临床前水平评估新型低血清阳性率载体。 INVECTA 在基础和转化腺病毒研究方面提供了一个跨学科和跨部门的网络，该网络将促进知识、技能和技术的转让，并促进基础和应用腺病毒生物学领域的培训。为了最大限度地实现知识共享，INVECTA将在联盟内借调研究人员，组织内部研讨会和培训课程，并根据开放科学模式大力鼓励参与专业研讨会、学校和会议。